Aspirin should be stopped at day 0 after PCI: pros and cons.
Publication
, Journal Article
Gurbel, P; Tantry, U; Guimarães, PO; Lemos, PA
Published in: EuroIntervention
April 3, 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
EuroIntervention
DOI
EISSN
1969-6213
Publication Date
April 3, 2023
Volume
18
Issue
16
Start / End Page
e1304 / e1306
Location
France
Related Subject Headings
- Platelet Aggregation Inhibitors
- Percutaneous Coronary Intervention
- Humans
- Aspirin
- 3201 Cardiovascular medicine and haematology
- 0104 Statistics
Citation
APA
Chicago
ICMJE
MLA
NLM
Gurbel, P., Tantry, U., Guimarães, P. O., & Lemos, P. A. (2023). Aspirin should be stopped at day 0 after PCI: pros and cons. EuroIntervention, 18(16), e1304–e1306. https://doi.org/10.4244/EIJ-E-23-00001
Gurbel, Paul, Udaya Tantry, Patricia O. Guimarães, and Pedro A. Lemos. “Aspirin should be stopped at day 0 after PCI: pros and cons.” EuroIntervention 18, no. 16 (April 3, 2023): e1304–6. https://doi.org/10.4244/EIJ-E-23-00001.
Gurbel P, Tantry U, Guimarães PO, Lemos PA. Aspirin should be stopped at day 0 after PCI: pros and cons. EuroIntervention. 2023 Apr 3;18(16):e1304–6.
Gurbel, Paul, et al. “Aspirin should be stopped at day 0 after PCI: pros and cons.” EuroIntervention, vol. 18, no. 16, Apr. 2023, pp. e1304–06. Pubmed, doi:10.4244/EIJ-E-23-00001.
Gurbel P, Tantry U, Guimarães PO, Lemos PA. Aspirin should be stopped at day 0 after PCI: pros and cons. EuroIntervention. 2023 Apr 3;18(16):e1304–e1306.
Published In
EuroIntervention
DOI
EISSN
1969-6213
Publication Date
April 3, 2023
Volume
18
Issue
16
Start / End Page
e1304 / e1306
Location
France
Related Subject Headings
- Platelet Aggregation Inhibitors
- Percutaneous Coronary Intervention
- Humans
- Aspirin
- 3201 Cardiovascular medicine and haematology
- 0104 Statistics